Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6511 to 6525 of 7680 results

  1. Lanreotide (subcutaneous injection) for treating unresectable locally advanced or metastatic, non-progressive gastroenteropancreatic tumours [ID961]

    Discontinued [GID-TA10026]

    Technology appraisal guidance
    Discontinued

  2. Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

    Discontinued [GID-TA10566]

    Technology appraisal guidance
    Discontinued

  3. Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

    Discontinued [GID-TA10763]

    Technology appraisal guidance
    Discontinued

  4. Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

    In development [GID-HST10032] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  5. Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

    Discontinued [GID-HST10004]

    Highly specialised technologies guidance
    Discontinued

  6. Idebenone for treating Duchenne muscular dystrophy [ID1092]

    Discontinued [GID-TA10310]

    Technology appraisal guidance
    Discontinued

  7. Bevacizumab in combination with chemotherapy for the second line treatment of HER2 negative metastatic breast cancer [ID488]

    Discontinued [GID-TAG432]

    Technology appraisal guidance
    Discontinued

  8. Omburtamab for treating relapsed neuroblastoma [ID1664]

    In development [GID-TA10608] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Avelumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID1146]

    Discontinued [GID-TA10341]

    Technology appraisal guidance
    Discontinued

  10. Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]

    Discontinued [GID-TAG423]

    Technology appraisal guidance
    Discontinued

  11. Personal, social, health and economic education focusing on sex and relationships and alcohol education

    Discontinued [GID-PHG0]

    NICE guideline
    Discontinued

  12. Juvenile idiopathic arthritis - abatacept [ID27]

    Discontinued [GID-TAG402]

    Technology appraisal guidance
    Discontinued

  13. Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]

    In development [GID-TAG499] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]

    Discontinued [GID-TA10164]

    Technology appraisal guidance
    Discontinued

  15. Constipation (opioid induced) - lubiprostone [ID646]

    Discontinued [GID-TAG367]

    Technology appraisal guidance
    Discontinued